Hu, Wenhua

First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers

Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 581

Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer

Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., Cole, S., & Aziz, N. (2009) · Clinical Cancer Research

Cancer survivorship and careTryptophan and brain disorders

Cited by 315